Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
CRISPR/CasRx suppresses KRAS-induced brain arteriovenous malformation developed in postnatal brain endothelial cells in mice
Shoji Saito, Yuka Nakamura, Satoshi Miyashita, Tokiharu Sato, Kana Hoshina, Masayasu Okada, Hitoshi Hasegawa, Makoto Oishi, Yukihiko Fujii, Jakob Körbelin, Yoshiaki Kubota, Kazuki Tainaka, Manabu Natsumeda, Masaki Ueno
Shoji Saito, Yuka Nakamura, Satoshi Miyashita, Tokiharu Sato, Kana Hoshina, Masayasu Okada, Hitoshi Hasegawa, Makoto Oishi, Yukihiko Fujii, Jakob Körbelin, Yoshiaki Kubota, Kazuki Tainaka, Manabu Natsumeda, Masaki Ueno
View: Text | PDF
Research Article Neuroscience

CRISPR/CasRx suppresses KRAS-induced brain arteriovenous malformation developed in postnatal brain endothelial cells in mice

  • Text
  • PDF
Abstract

Brain arteriovenous malformations (bAVMs) are anomalies forming vascular tangles connecting the arteries and veins, which cause hemorrhagic stroke in young adults. Current surgical approaches are highly invasive, and alternative therapeutic methods are warranted. Recent genetic studies identified KRAS mutations in endothelial cells of bAVMs; however, the underlying process leading to malformation in the postnatal stage remains unknown. Here we established a mouse model of bAVM developing during the early postnatal stage. Among 4 methods tested, mutant KRAS specifically introduced in brain endothelial cells by brain endothelial cell–directed adeno-associated virus (AAV) and endothelial cell–specific Cdh5-CreERT2 mice successfully induced bAVMs in the postnatal period. Mutant KRAS led to the development of multiple vascular tangles and hemorrhage in the brain with increased MAPK/ERK signaling and growth in endothelial cells. Three-dimensional analyses in cleared tissue revealed dilated vascular networks connecting arteries and veins, similar to human bAVMs. Single-cell RNA-Seq revealed dysregulated gene expressions in endothelial cells and multiple cell types involved in the pathological process. Finally, we employed CRISPR/CasRx to knock down mutant KRAS expression, which efficiently suppressed bAVM development. The present model reveals pathological processes that lead to postnatal bAVMs and demonstrates the efficacy of therapeutic strategies with CRISPR/CasRx.

Authors

Shoji Saito, Yuka Nakamura, Satoshi Miyashita, Tokiharu Sato, Kana Hoshina, Masayasu Okada, Hitoshi Hasegawa, Makoto Oishi, Yukihiko Fujii, Jakob Körbelin, Yoshiaki Kubota, Kazuki Tainaka, Manabu Natsumeda, Masaki Ueno

×

Figure 4

Histopathological changes in the lesions of KRASG12D-induced Cdh5-CreERT2;lsl-tdTomato mice.

Options: View larger image (or click on image) Download as PowerPoint
Histopathological changes in the lesions of KRASG12D-induced Cdh5-CreERT...
(A and B) Representative images of pERK expression in tdTomato+ endothelial cells in the lesion of AAV-DIO-KRASG12D and tamoxifen-injected Cdh5-CreERT2;lsl-tdTomato mice (1 × 109 GC, P16, P21). (C) Quantified pERK expression in tdTomato+ endothelial cells in the lesion and adjacent control area. n = 9 lesions in 3 animals, unpaired t test. (D–F) Ki67 expression in the lesion (arrowheads, P16, P21). (G and H) Quantification of Ki67+ cells in tdTomato+ endothelial cells (%) and Ki67+ tdTomato– cells in the lesion and adjacent control area. n = 4 animals, Mann-Whitney U test (G) and unpaired t test (H). (I and J) Cell and nuclear area of tdTomato+ endothelial cells in the lesion and adjacent control area. n = 9 lesions in 3 animals, unpaired t test (I) and Mann-Whitney U test (J). (K) H&E staining showing hemorrhage and hemosiderin-laden macrophages/microglia (arrowheads) in the lesion (P16, P21). (L) Iron staining with Prussian blue in the lesion (blue, arrowheads). (M and N) Activated Iba1+ microglia/macrophages and GFAP+ astrocytes surrounding the lesion (P16, 21). (O and P) Quantification of Iba1+ (O) and GFAP+ cell areas (P) in the lesion and adjacent control area. n = 9 lesions in 3 animals, unpaired t test. (Q) Ly6G+ neutrophils, B220+ B cells, CD3+ T cells, and MPO+ neutrophils in the lesion (arrowheads). (R and S) Quantification of Ly6G+ (R) and B220+ cells (S) in the lesion and adjacent control area. n = 3 animals, unpaired t test. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. Scale bars: 100 μm (A, B, D–F, and K–N), 20 μm (Q).

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts